BridgeMD
Compares treatment options for Idiopathic Hyperaldosteronism
Official title Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
ClinicalTrials.gov ID: NCT07328230
What this study is testing
What is Spironolactone?
Spironolactone is an investigational medicine, being studied as a potential treatment for idiopathic hyperaldosteronism.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 15 to 60
You may be able to join if
- Aged from 15 to 60 with no limits in sex;
- Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines;
- Sub-typing diagnosis confirmed idiopathic hyperaldosteronism;
- Patients or their legal representatives have to sign written informed consent approved by the ethics committee.
You likely can't join if
- Unilateral adrenal hyperplasia;
- Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) \ 176 μmol/L；
- Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months;
- Severe contrast agent allergy;
- Women who are pregnant or planning to become pregnant;
- Patients with other serious organic diseases cannot tolerate SAAE treatment;
See the full eligibility criteria
- Aged from 15 to 60 with no limits in sex;
- Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines;
- Sub-typing diagnosis confirmed idiopathic hyperaldosteronism;
- Patients or their legal representatives have to sign written informed consent approved by the ethics committee.
- Unilateral adrenal hyperplasia;
- Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) \ 176 μmol/L；
- Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months;
- Severe contrast agent allergy;
- Women who are pregnant or planning to become pregnant;
- Patients with other serious organic diseases cannot tolerate SAAE treatment;
- Other forms of secondary hypertension.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Nanchang, Jiangxi, China
- Chengdu, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 15 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Nanchang, Jiangxi, China; Chengdu, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.